Klaria Pharma Holding AB (FRA:6FN) Scaled Net Operating Assets: -0.52 (As of Mar. 2026)


FRA:6FN Klaria Pharma Holding AB FRA:6FN
28 GF Score
Price €0.06
GF Value €0.03
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Klaria Pharma Holding AB Scaled Net Operating Assets?

Klaria Pharma Holding AB FRA:6FN -8.28% 28 Scaled Net Operating Assets is -0.52 as of Mar. 2026. GuruFocus rates FRA:6FN with a GF Score™ of 28/100 and a GF Value™ of €0.03 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Klaria Pharma Holding AB's operating assets for the quarter that ended in Mar. 2026 was €2.76 Mil. Klaria Pharma Holding AB's operating liabilities for the quarter that ended in Mar. 2026 was €4.70 Mil. Klaria Pharma Holding AB's Total Assets for the quarter that ended in Dec. 2025 was €3.75 Mil. Therefore, Klaria Pharma Holding AB's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was -0.52.


Klaria Pharma Holding AB Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Klaria Pharma Holding AB's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Klaria Pharma Holding AB Scaled Net Operating Assets Chart

Klaria Pharma Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.57 0.60 0.48 0.34 -0.08

Klaria Pharma Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.37 0.04 -0.09 -0.52

FRA:6FN vs ZTS, UTHR: Scaled Net Operating Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Klaria Pharma Holding AB's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Klaria Pharma Holding AB Scaled Net Operating Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Klaria Pharma Holding AB's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Klaria Pharma Holding AB's Scaled Net Operating Assets falls into.


FRA:6FN
28GF Score
Klaria Pharma Holding AB FRA:6FN
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Klaria Pharma Holding AB Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Klaria Pharma Holding AB's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(3.715-4.102)/4.979
=-0.08

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=3.746 - 0.031
=3.715

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=4.102 - 0 - 0
=4.102

Klaria Pharma Holding AB's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(2.762-4.699)/3.746
=-0.52

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=2.786 - 0.024
=2.762

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=4.699 - 0 - 0
=4.699

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -0.52 mean?
Klaria Pharma Holding AB (FRA:6FN) has a Scaled Net Operating Assets of -0.52 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Klaria Pharma Holding AB and its competitors.
Is Klaria Pharma Holding AB's Scaled Net Operating Assets too high?
Klaria Pharma Holding AB's current Scaled Net Operating Assets is -0.52. Overall, Klaria Pharma Holding AB has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Klaria Pharma Holding AB's Scaled Net Operating Assets compare to ZTS and UTHR?
Klaria Pharma Holding AB's Scaled Net Operating Assets of -0.52 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Drug Manufacturers company?
A good Scaled Net Operating Assets depends on the Drug Manufacturers industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Klaria Pharma Holding AB and its competitors. Klaria Pharma Holding AB's current Scaled Net Operating Assets is -0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Klaria Pharma Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Klaria Pharma Holding AB (FRA:6FN) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.03, compared to a current price of €0.06 — trading 106.3% above its estimated fair value. The current Scaled Net Operating Assets is -0.52. Klaria Pharma Holding AB's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Klaria Pharma Holding AB (FRA:6FN), the current Scaled Net Operating Assets is -0.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Klaria Pharma Holding AB (FRA:6FN) Overvalued in 2026?

Based on GuruFocus' analysis, Klaria Pharma Holding AB stock appears to be overvalued. The current stock price of €0.06 is trading 106.3% above its estimated GF Value™ of €0.03. GuruFocus considers Klaria Pharma Holding AB to be Significantly Overvalued.

Key valuation signals for FRA:6FN:

  • Scaled Net Operating Assets: -0.52
  • GF Value™: €0.03 vs. price of €0.06 (106.3% above fair value)
  • GF Score™: 28/100 with 6 warning signs

No single metric tells the full story. See the FRA:6FN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Klaria Pharma Holding AB Business Description

Other Exchanges KLAR:Sweden
Address Virdings Alle 2, Uppsala, CHE, 754 50
Klaria Pharma Holding AB is a Swedish pharmaceutical company that develops rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Its patented drug delivery platform consists of an alginate-based polymer film that enables the absorption of a product's active substance through the oral mucosa.
28GF Score

Get the complete analysis for FRA:6FN

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.06
Price
€0.03
GF Value